Reported Earlier, Autolus Therapeutics Presents Results From Pivotal Phase 2 FELIX Study In Adult r/r B-ALL At ASCO
Portfolio Pulse from Happy Mohamed
Autolus Therapeutics announced positive results from its Phase 2 FELIX study of obe-cel in adult r/r B-ALL at the ASCO Annual Meeting. The study met its primary endpoint with 76% of patients achieving a response, and demonstrated potential best-in-class tolerability. Manufacturing was reliable, with 84% of enrolled patients receiving obe-cel.
June 02, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Autolus Therapeutics' Phase 2 FELIX study of obe-cel in adult r/r B-ALL showed positive results, meeting its primary endpoint with a 76% response rate and demonstrating potential best-in-class tolerability.
The positive results from the Phase 2 FELIX study indicate that Autolus Therapeutics' obe-cel has the potential for long-term clinical benefit in adult B-ALL patients. The high response rate and potential best-in-class tolerability are likely to have a positive impact on the company's stock price in the short term, as it demonstrates the effectiveness of the treatment and its potential for commercial success.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100